WO1990000606A1 - Polynucleotides codant le noyau peptidique de proteoglycanes humains des cellules effectrices de la reponse immunitaire - Google Patents

Polynucleotides codant le noyau peptidique de proteoglycanes humains des cellules effectrices de la reponse immunitaire Download PDF

Info

Publication number
WO1990000606A1
WO1990000606A1 PCT/US1989/003051 US8903051W WO9000606A1 WO 1990000606 A1 WO1990000606 A1 WO 1990000606A1 US 8903051 W US8903051 W US 8903051W WO 9000606 A1 WO9000606 A1 WO 9000606A1
Authority
WO
WIPO (PCT)
Prior art keywords
proteoglycan
peptide core
core protein
human
peptide
Prior art date
Application number
PCT/US1989/003051
Other languages
English (en)
Inventor
Richard L. Stevens
John H. Weis
Christopher F. Nicodemus
Original Assignee
Brigham And Women's Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham And Women's Hospital filed Critical Brigham And Women's Hospital
Publication of WO1990000606A1 publication Critical patent/WO1990000606A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Definitions

  • the present invention is directed to the purification of human secretory granule proteoglycan and production of the peptide core thereof by recombinant DNA technology. It is also directed to the production of antibodies against human secretory granule proteoglycan.
  • Secretory granule proteoglycans comprise one of several families of mammalian proteoglycans, all of which are highly acidic macro- molecules possessing at least one sulfated, glycosaminoglycan chain covalently bound to a peptide core. Tantravahi, R.V., et al., Proc. Natl. Acad. Sci. USA 83:9207 (1986).
  • Various proteoglycan families have been proposed in the human based on differential reactivity to panels of monoclonal antibodies, differential peptide mapping after proteolytic treatment, different sizes after translation, and, in some cases, different amino acid sequences.
  • proteoglycans that are localized to extracellular matrices appear to belong to a family that is distinct from the subfamily of more hydrophobic proteoglycans intercalated into the plasma membrane. Tantravahi, R.V., et al., supra.
  • proteoglycan peptide cores Although there are at least 12 distinct proteins in the human that exist as proteoglycan peptide cores, the complete primary structure and/or chromosomal location of only a few of these proteoglycans are presently known and ho gene has been isolated that encodes the complete peptide core of any proteoglycan.
  • a cDNA that encodes the dermatan sulfate proteoglycan peptide core that resides in the extracellular matrix around fibroblasts has been cloned from a human embryonic fibroblast cell line. Krusius, T., and Ruoslahti, E., Proc. Natl. Acad. Sci., USA 83:7683 (1986). Its nucleotide sequence predicts a peptide core of 40,000 M r with three potential glycosaminoglycan initiation sites and three potential sites for N-linked oligosaccharides.
  • Cell surface glycoproteins may also exist as proteoglycans.
  • the transferrin receptor and the invariant chain of the class II antigens have been reported to be proteoglycans on the plasma membrane of human skin fibroblasts and human lymphoid tissues, respectively. Giacoletto, K.S., et al., J. EXP. Med. 164:1422 (1986).
  • the deduced amino acid sequence of the cDNAs that encode the transferrin receptor and the invariant protein have revealed serine- glycine glycosaminoglycan initiation sites.
  • Another proteoglycan which contains chondroitin sulfate glycosaminoglycans has been described on the surfaces of human melanoma cells.
  • proteoglycans stored within the granules of a cell were obtained from studies of the rat skin mast cell.
  • a number of cells which participate in immune and inflammatory responses including mucosal mast cells, basophils, eosinophils, neutrophils, macrophages, platelets, and natural killer cells, also contain proteoglycans in their granules.
  • the presence of a family of proteoglycans that resides inside cells rather than on the plasma membrane or in the extracellular matrix suggests that these molecules may be important in the functions of such cells for tumor surveillance and host defense against bacterial, viral, fungal, and parasitic pathogens.
  • a rat chondroitin sulfate proteoglycan peptide core cDNA was identified and sequenced.
  • the selection of the cDNA clone pPG-1 from a cDNA library prepared from L2 rat yolk sac tumor poly(A) + mRNA was accomplished by using oligonucleotides derived from two regions of the W-t ⁇ - terminal protein sequence of the L2 proteoglycan.
  • the use of oligonucleotides from two different parts of the NH 2 -terminal amino acid sequence was essential for the identification of the desired cDNA clones.
  • the amino acid sequence inferred from the pPG-1 proteoglycan peptide core cDNA clone revealed the complete primary structure of the mature proteoglycan peptide core produced by this rat tumor cell.
  • the proteoglycan peptide core coding region identified on the basis of inferred amino acid sequence homology with the proteoglycan peptide core NH 2 -terminal amino acid sequence, codes for a 104 amino acid core protein with a calculated molecular weight of 10,190 daltons.
  • the amino acid sequence of the rat L2 cell proteoglycan peptide core contains three structural regions beginning with a 14 amino acid NH 2 -terminal region followed by a 49 amino acid serine-glycine repeat region and a 41 amino acid COOH-terminal region.
  • the functions of the NH 2 - and COOH-terminal regions are unknown, although it is thought that they play a role in determining interactions between the proteoglycan and both cell surfaces and extracellular molecules.
  • the function of the serine-glycine repeat region in the middle of the molecule is to serve- as a recognition and receptor site for the attachment of chondroitin sulfate side chains.
  • the attachment of chondroitin sulfate and heparin chains onto all proteoglycan cores is accomplished via O-glycosyl linkage to serine.
  • glycine residues are also involved in glycosaminoglycan attachment, since glycine is abundant in proteoglycans, and synthetic peptides containing alternating serine and glycine can serve as acceptors for glycosaminoglycan chain initiation.
  • the extent of serine O-glycosyl ation in the L2 proteoglycan has been estimated to be near 60%, indicating that at least 14 of the serine residues of the core protein bear a chondroitin sulfate chain.
  • Bourdon et al. noted that the structure of the serine-glycine region closely parallels that predicted for the glycosaminoglycan attachment region of a rat heparin proteoglycan, indicating that the serine- glycine repeat may be a general feature of at least a subset of proteoglycans.
  • pronase-resistant glycosaminoglycan attachment region of rat mast cell heparin proteoglycan contains only serine and glycine amino acids, it was proposed that 15-20 serine residues alternate with glycine residues, with heparin chains being attached to at least two of every three serines. It would appear that at least two proteoglycans, the rat mast cell heparin proteoglycan and the rat yolk sac tumor proteoglycan, have identical or nearly identical glycosaminoglycan attachment regions.
  • codon usage for serine and glycine is quite restricted in the pPG-1 cDNA, with 81% of the serine residues being coded for by two of six possible codons and 70% of the glycine residues being coded for by one of its four possible codons.
  • proteoglycans In addition to chondroitin sulfate side chains, many other proteoglycans have 0- and N-linked oligosaccharides. These oligo- saccharide chains are linked to the proteoglycan peptide core through either threonine (serine) O-glycosyl or asparagine N-glycosyl acceptor recognition sequences.
  • An examination of the rat L2 cell proteoglycan peptide core amino acid sequence does not reveal any asparagine oligosaccharide acceptor sites that have the sequence X-asparagine-Y-serine. Bourdon, M.A. et al., suora: Hughes, R.C., Prog. Biophvs. Mol. Biol. 26:189-268 (1973).
  • mouse mast cell chondroitin sulfate E is similar to the rat serosal mast cell heparin proteoglycan in that both are packaged in secretory granules, are protease-resis- tant, and have highly sulfated glycosaminoglycans, and have peptide cores which are rich in serine and glycine.
  • the mouse chondroitin sulfate E proteoglycan has a peptide core somewhat similar to the chondroitin sulfate proteoglycan isolated by Bourdon et al., supra, from the rat yolk sac's tumor in size and in Ser, Gly, and Glx content.
  • BMMC mouse bone marrow derived mast cells
  • rat serosal mast cells cells that contain intracellular heparin proteoglycan
  • the invention relates to the identification, characterization, and sequencing of cDNAs and genomic fragments which encode the secretory granule proteoglycan peptide core protein that is present in human promyelocytic leukemia cell line HL-60.
  • genetic sequences encoding human secretory granule proteoglycan peptide core protein.
  • the invention also provides for expression vectors containing such genetic sequences, hosts transformed with such expression vectors, and methods for producing the genetically engineered or recombinant secretory granule proteoglycan peptide core protein.
  • the present invention also provides genetic sequences encoding human secretory granule proteoglycan peptide core protein antisense RNA, expression vectors containing such genetic sequences, hosts transformed with such expression vectors, methods for producing the genetically engineered or recombinant antisense RNA, and methods for the inhibition of expression of the human proteoglycan peptide core protein gene expression using these vectors.
  • the invention further provides antibodies which specifically recognize human secretory granule proteoglycan.
  • the antibodies were raised against consensus polypeptides whose sequences are based on the consensus sequence of the cDNAs encoding this protein.
  • the secretory granule proteoglycan cDNA, recombinant protein, antisense RNA and antibodies provided by the invention are useful as diagnostic probes for monitoring the activation and involvement of immune effector cells in health and disease.
  • this proteoglycan is released from the human natural killer cell during its killing of tumor cells, the antibodies can be used in diagnosing and monitoring cancer. In another example, because this proteoglycan is also released by mast cells during immunologic activation, the antibodies can be used to monitor inflammation and allergic disorders. Further, because human secretory granule proteoglycan peptide core protein is expressed in the inflammatory response which accompanies tissue injury and repair and some immunological responses, antibodies raised against human secretory granule proteoglycan peptide core protein can be used in assays to detect, and follow the course of, such reactions in humans.
  • proteoglycan peptide core of this family of proteoglycans will be the same in different human hematopoietic cells, the antibody of the invention will recognize all secretory granule proteoglycan peptide cores of hematopoietic effector cells.
  • the secretory granule proteoglycan interacts with proteases.
  • mast cell proteases When mast cell proteases are bound to this proteoglycan, their degradative activity against large substrates is greatly diminished. Therefore, they may also be useful in vitro and in vivo as specific proteolytic inhibitors.
  • FIG. 1 Restriction map and nucleotide sequencing strategy of CDNA-H4 and its related cDNA.
  • the cDNA-H4 originated from HL-60 cells.
  • "X” and “A” refer to the sites within each cDNA which are susceptible to Xmnl and AccI, respectively.
  • the arrows indicate the direction and length of each subcloned fragment of cDNA that was sequenced.
  • Figure 3 Restriction map of the human secretary granule proteoglycan peptide core gene isolated from a human leukocyte genomic DNA library (Klickstein, L.B. et al., J. Exo. Med. 165:1095-1112 (1987)).
  • Figure 4 Nucleotide sequence of the gene that encodes the peptide core of human secretory granule proteoglycans. The nucleotide sequences of the 5' flanking region, the exon/intron junctions, and the three exons are depicted. The hydrophobic signal peptide of the translated proteoglycan peptide core in exon 1 and the serine-glycine rich glycosaminoglycan attachment region in exon 3 are boxed. The polyadenylation site in exon 3 is underlined.
  • FIG. 5 Nucleotide sequence of the mouse gene that encodes the peptide core of mouse secretory granule proteoglycans. The nucleotide sequence of the 5' flanking region, the exon/intron junctions, and the three exons are depicted. The arrow indicates the probable transcription-initiation site. The hydrophobic signal peptide of the translated proteoglycan peptide core is boxed in exon 1. The di-acidic amino acid sequence that has been proposed to dictate glycosaminoglycan addition to proteins and the serine-glycine glycosaminoglycan attachment region are boxed in exon 3. The polyadenylation site in exon 3 is underlined. Figure 6. ELISA of the rabbit anti-peptide 02 serum.
  • Peptides 01 (o--o) and 02 (•--•) were coupled to separate microtiter wells and different dilutions of the rabbit anti-peptide 02 sera were examined for their reactivity against the specific peptide as detected spectro- photometrically at 490 nm after the addition of horseradish peroxid- ase-conjugated goat anti-rabbit antibody followed by 2,2'azino-di-[3- ethyl-benzthiazoline] sulfonate.
  • FIG. 7 SDS-PAGE analysis of immunoprecipitates of lysates of [ 35 S]sulfate-labeled (A) and [ 35 S]methionine-labeled (B) HL-60 cells.
  • A Lysates of [ 35 S]sulfatf-labeled HL-60 cells were analyzed before (lane 1) and after immunoprecipitation with anti-peptide 02 IgG in the presence (lane 2) or absence (lane 3) of peptide 02.
  • rDNA recombinant DNA
  • RNA sequence containing a template for a RNA polymerase The RNA transcribed from a gene may or may not code for a protein. RNA that codes for a protein is termed messenger RNA (mRNA) and, in eukaryotes, is transcribed by RNA polymerase II. However, it is also known to construct a gene containing a RNA polymerase II template wherein a RNA sequence is transcribed which has a sequence complementary to that of a specific mRNA but is not normally translated.
  • mRNA messenger RNA
  • RNA polymerase II it is also known to construct a gene containing a RNA polymerase II template wherein a RNA sequence is transcribed which has a sequence complementary to that of a specific mRNA but is not normally translated.
  • Antisense RNA gene Such a gene construct is herein termed an “antisense RNA gene” and such a RNA transcript is termed an “antisense RNA.” Antisense RNAs are not normally translatable due to the presence of translational stop codons in the antisense RNA sequence.
  • a “complementary DNA” or “cDNA” gene includes recombinant genes synthesized by reverse transcription of mRNA and from which intervening sequences (introns) have been removed.
  • Cloning vehicle A plasmid or phage DNA or other DNA sequence which is able to replicate autonomously in a host cell, and which is characterized by one or a small number of endonuclease recognition sites at which such DNA sequences may be cut in a determinable fashion without loss of an essential biological function of the vehicle, and into which DNA may be spliced in order to bring about its replication and cloning.
  • the cloning vehicle may further . contain a marker suitable for use in the identification of cells transformed with the cloning vehicle. Markers, for example, are tetracycline resistance or ampicillin resistance. The word "vector” is sometimes used for "cloning vehicle.”
  • Expression vehicle A vehicle or vector similar to a cloning vehicle but which is capable of expressing a gene which has been cloned into it, after transformation into a host.
  • the cloned gene is usually placed under the control of (i.e., operably linked to) certain control sequences such as promoter sequences.
  • Expression control sequences will vary depending on whether the vector is designed to express the operably linked gene in a prokaryotic or eukaryotic host and may additionally contain transcriptional elements such as enhancer elements, termination sequences, tissue-specificity elements, and/or translational initiation and termination sites.
  • Proteoglycan This term as used throughout the specification and claims means "human secretory proteoglycan" which may or may not contain glycosaminoglycan chains covalently bound to the proteo- glycan's core protein.
  • the term is also meant to include peptide fragments of human secretory proteoglycan wherein the peptide core protein contains less than the naturally-occurring number of amino acids, such as partial fragments of proteoglycan which retain biological (functional or structural) activity.
  • An example of a functional activity is the ability to induce a specific biological response in the same manner that the native non-recombinant protein does.
  • An example of a structural activity is the ability to bind antibodies which also recognize the native non-recombinant protein.
  • the term is also used to include any peptide which comprises the sequence of a naturally-occurring human secretory granule proteoglycan peptide core protein or an analog thereof together with one or more flanking amino acids, which show human secretory proteoglycan biological (functional or structural) activity.
  • the present invention pertains both to expression of full-length human secretory granule proteoglycan peptide core protein, and to the functional derivatives of this protein.
  • a “functional derivative” of human secretory granule proteoglycan peptide core protein is a protein which possesses a biological activity (either functional or structural) that is substantially similar to a biological activity of non-recombinant human secretory granule proteoglycan.
  • a functional derivative of human secretory granule proteoglycan peptide core protein may or may not contain post-translational modifications such as covalently linked carbohydrate, depending on the necessity of such modifications for the performance of a specific function.
  • the term “functional derivative” is intended to include the “fragments,” “variants,” “analogues,” or “chemical derivatives" of a molecule.
  • a "fragment" of a molecule such as human secretory granule proteoglycan is meant to refer to any variant of the molecule, such as the peptide core, or a variant of the peptide core.
  • variants of a molecule such as human secretory granule proteoglycan is meant to refer to a molecule substantially similar in structure and biological activity to either the entire molecule, or to a fragment thereof. Thus, provided that two molecules possess a similar activity, they are considered variants as that term is used herein even if the composition or secondary, tertiary, or quaternary structure of one of the molecules is not identical to that found in the other, or if the sequence of amino acid residues is not identical.
  • Analog of a molecule such as human secretory granule proteoglycan is meant to refer to a molecule substantially similar in function to either the entire molecule or to a fragment thereof.
  • a molecule is said to be a "chemical derivative" of another molecule when it contains additional chemical moieties not normally a part of the molecule. Such moieties may improve the molecule's solubility, absorption, biological half life, etc. The moieties may alternatively decrease the toxicity of the molecule, eliminate or attenuate any undesirable side effect of the molecule, etc. Moieties capable of mediating such effects are disclosed in Remington's Pharmaceutical Sciences (1980). Procedures for coupling such moieties to a molecule are well known in the art.
  • This invention comprises the amino acid sequence of human secretory granule proteoglycan peptide core protein, genetic sequences coding for the proteoglycan peptide core protein mRNA or antisense mRNA, expression vehicles containing the genetic sequences, hosts transformed therewith and recombinant human secretory granule proteoglycan peptide core protein and antisense RNA produced by such transformed host expression.
  • the invention further comprises antibodies directed against the human secretory granule proteoglycan peptide core protein.
  • the process for genetically engineering human secretory granule proteoglycan peptide core sequences is facilitated through the cloning of genetic sequences which are capable of encoding the peptide core and through the expression of such genetic sequences.
  • the term "genetic sequences" is intended to refer to a nucleic acid molecule (preferably DNA).
  • Genetic sequences which are capable of encoding the peptide core of the human secretory granule proteoglycan are derived from a variety of sources. These sources include genomic DNA, cDNA, synthetic DNA, and combinations thereof.
  • the preferred source of the genomic DNA or mRNA is the human promyelocytic leukemia cell line, HL-60.
  • the secretory granule proteoglycan peptide core protein genomic DNA of the invention may or may not include naturally occurring introns. Moreover, such genomic DNA may be obtained in association with the 5' promoter region of the human secretory granule proteoglycan peptide core protein gene sequences and/or with the 3' transcriptional termination region. Further, such genomic DNA may be obtained in association with the genetic sequences which encode the 5' non-translated region of the human secretory granule proteoglycan peptide core protein mRNA and/or with the genetic sequences which encode the 3' non-translated region.
  • Human secretory granule proteoglycan peptide core protein genomic DNA can be extracted and purified from any cell containing human chromosome 10 by means well known in the art (for example, see Guide to Molecular Cloning Technioues. S.L. Berger et al., eds., Academic Press (1987)).
  • human secretory granule proteoglycan peptide core protein mRNA can be isolated from any cell which produces or expresses human secretory granule proteoglycan, and used to produce cDNA by means well known in the art (for example, see Guide to Molecular Cloning Technioues. S.L. Berger et al., eds., Academic Press (1987)).
  • the mRNA preparation used will be enriched in mRNA coding for human secretory granule proteoglycan peptide core protein, either naturally, by isolation from a cells which are producing large amounts of the protein, or in vitro, by techniques commonly used to enrich mRNA preparations for specific sequences, such as sucrose gradient centrifugation, or both.
  • DNA preparations either human genomic DNA or cDNA
  • suitable DNA preparations are randomly sheared or enzymatically cleaved, respectively, and ligated into appropriate vectors to form a recombinant gene (either genomic or cDNA) library.
  • a DNA sequence encoding human secretory granule proteoglycan peptide core protein or its functional derivatives may be inserted into a DNA vector in accordance with conventional techniques, including blunt-ending or staggered-ending termini for ligation, restriction enzyme digestion to provide appropriate termini, filling in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and ligation with appropriate ligases.
  • Libraries containing human secretory granule proteoglycan peptide core protein clones may be screened and a human secretory granule proteoglycan peptide core protein clone identified by any means which specifically selects for human secretory granule proteoglycan peptide core protein DNA such as, for example, a) by hybridization with an appropriate nucleic acid probe(s) containing a sequence specific for the DNA of this protein, or b) by hybridization-selected translational analysis in which native mRNA which hybridizes to the clone in question is translated in vitro and the translation products are further characterized, or, c) if the cloned genetic sequences are themselves capable of expressing mRNA, by immunoprecipitation of a translated human secretory granule proteoglycan peptide core protein product produced by the host
  • Oligonucleotide probes specific for human secretory granule proteoglycan peptide core protein which can be used to identify clones to this protein can be designed from knowledge of the amino acid sequence of the protein's peptide core.
  • the sequence of amino acid residues in a peptide is designated herein either through the use of their commonly employed three-letter designations or by their single-letter designations. A listing of these three-letter and one-letter designations may be found in textbooks such as Biochemistry. Lehninger, A., Worth Publishers, New York, NY (1970).
  • the amino acid sequence is listed horizontally, the amino terminus is intended to be on the left end whereas the carboxy terminus is intended to be at the right end.
  • the residues of amino acids in a peptide may be separated by hyphens. Such hyphens are intended solely to facilitate the presentation of a sequence.
  • the genetic code is degenerate, more than one codon may be used to encode a particular amino acid (Watson, J.D., In: Molecular Biology of the Gene. 3rd Ed., W.A. Benjamin, Inc., Menlo Park, CA (1977), pp. 356-357).
  • the peptide fragments are analyzed to identify sequences of amino acids which may be encoded by oligonucleotides having the lowest degree of degeneracy. This is preferably accomplished by identifying sequences that contain amino acids which are encoded by only a single codon.
  • amino acid sequence may be encoded by only a single oligonucleotide sequence
  • amino acid sequence may be encoded by any of a set of similar oligonucleotides.
  • all of the members of this set contain oligonucleotide sequences which are capable of encoding the same peptide fragment and, thus, potentially contain the same oligonucleotide sequence as the gene which encodes the peptide fragment
  • only one member of the set contains the nucleotide sequence that is identical to the exon coding sequence of the gene.
  • this member is present within the set, and is capable of hybridizing to DNA even in the presence of the other members of the set, it is possible to employ the unfractionated set of oligonucleotides in the same manner in which one would employ a single oligonucleotide to clone the gene that encodes the peptide.
  • one or more different oligonucleotides can be identified from the amino acid sequence, each of which would be capable of encoding the human secretory granule proteoglycan.
  • the probability that a particular oligonucleotide will, in fact, constitute the actual human secretory granule proteoglycan encoding sequence can be estimated by considering abnormal base pairing relationships and the frequency with which a particular codon is actually used (to encode a particular amino acid) in eukaryotic cells.
  • Such “codon usage rules” are disclosed by Lathe, R., et al.. J. Molec. Biol. 183:1-12 (1985). Using the "codon usage rules" of Lathe, a single oligonucleotide sequence, or a set of oligonucleotide sequences, that contain a theoretical "most probable" nucleotide sequence capable of encoding the human secretory granule proteoglycan sequences is identified.
  • the suitable oligonucleotide, or set of oligonucleotides, which is capable of encoding a fragment of the human secretory granule proteoglycan peptide core protein gene (or which is complementary to such an oligonucleotide, or set of oligonucleotides) may be synthesized by means well known in the art (see, for example, Synthesis and Application of DNA and RNA. S.A. Narang, ed., 1987, Academic Press, San Diego, CA) and employed as a probe to identify and isolate the cloned human secretory granule proteoglycan peptide core protein gene by techniques known in the art.
  • the above-described DNA probe is labeled with a detectable group.
  • detectable group can be any material having a detectable physical or chemical property. Such materials have been well -developed in the field of nucleic acid hybridization and in general most any label useful in such methods can be applied to the present invention. Particularly useful are radioactive labels, such as 32 P, 3 H, 14 C, 35 S, 125 I, or the like. Any radioactive label may be employed which provides for an adequate signal and has a sufficient half-life.
  • the oligonucleotide may be radioactively labeled, for example, by "nick-translation" by well-known means, as described in, for example, Rigby, P.J.W., et al., J. Mol. Biol. 113:237 (1977) and by T4 DNA polymerase replacement synthesis as described in, for example, Deen, K.C., et al., Anal. Biochem. 135:456 (1983).
  • polynucleotides are also useful as nucleic acid hybridization probes when labeled with a non-radioactive marker such as biotin, an enzyme or a fluorescent group. See, for example, Leary, J.J., et al., Proc. Natl. Acad. Sci. USA 80:4045 (1983); Renz, M., et al., Nucl. Acids Res. 12:3435 (1984); and Renz, M., EMBO J. 6:817 (1983).
  • the actual identification of human secretory granule proteoglycan peptide sequences permits the identification of a theoretical "most probable" DNA sequence, or a set of such sequences, capable of encoding such a peptide.
  • a DNA molecule or set of DNA molecules, capable of functioning as a probe(s) for the .identification and isolation of clones containing the human secretory granule proteoglycan gene.
  • a library is prepared using an expression vector, by cloning DNA or, more preferably cDNA prepared from a cell capable of expressing human secretory granule proteoglycan, into an expression vector.
  • the library is then screened for members which express human secretory granule proteoglycan peptide core protein, for example, by screening the library with antibodies to the protein.
  • a previously described rat L2 cell-derived cDNA to a related proteoglycan, pPG-1, disclosed in Bourdon et al., Proc. Natl. Acad. Sci. USA 82:1322 (1985) is used to identify a human cDNA or genomic sequence encoding secretory granule proteoglycan peptide core protein.
  • Southern blots of digested human genomic DNA may be probed with nick-translated pPG-1 or pPG-M (a gene specific 489 bp Ssp I -- > 3'end fragment of pPG-1), Tantravahi et al., Proc. Natl. Acad. Sci.
  • Such characteristics may include the ability to specifically bind human secretory granule proteoglycan antibody, the ability to elicit the production of antibody which are capable of binding to human secretory granule proteoglycan, the ability to provide an human secretory granule proteoglycan-associated function to a recipient cell, among others.
  • human secretory granule proteoglycan peptide core protein transcriptional and translational signals recognizable by an appropriate host are necessary.
  • the cloned human secretory granule proteoglycan peptide core protein encoding sequences obtained through the methods described above, and preferably in a double-stranded form, may be operably linked to sequences controlling transcriptional expression in an expression vector, and introduced into a host cell, either prokaryote or eukaryote, to produce recombinant human secretory granule proteoglycan peptide core protein or a functional derivative thereof.
  • human secretory granule proteoglycan peptide core protein encoding sequence is operably linked to the sequences controlling transcriptional expression, it is also possible to express human secretory granule proteoglycan peptide core protein antisense RNA or a functional derivative thereof.
  • the present invention encompasses the expression of the human secretory granule proteoglycan peptide core protein, or a functional derivative thereof, in eukaryotic cells, and especially mammalian, insect and yeast cells.
  • eukaryotic hosts are mammalian cells either in vivo, or in tissue culture. Mammalian cells provide post- trans! ational modifications to recombinant proteoglycan peptide core protein which include folding and/or glycosylation at sites similar or identical to that found for the native proteoglycan.
  • mammalian host cells include rat-1 fibroblasts, mouse bone marrow derived mast cells, mouse mast cells immortalized with Kirsten sarcoma virus, or normal mouse mast cells that have been co-cultured with mouse fibroblasts.
  • Razin et al. J. of Immun. 132:1479 (1984); Levi-Schaffer et al., Proc. Natl. Acad. Sci. (USA) 83:6485 (1986) and Reynolds et al., "Immortalization of Murine Connective Tissue-type Mast Cells at Multiple Stages of Their Differentiation by Coculture of Splenocytes with Fibroblasts that Produce Kirsten Sarcoma Virus," J. Biol. Chem. 263:12783-12791 (1988). See Example 5, below.
  • a nucleic acid molecule such as DNA, is said to be "capable of expressing" a polypeptide if it contains expression control sequences which contain transcriptional regulatory information and such sequences are “operably linked” to the nucleotide sequence which encodes the polypeptide.
  • An operable linkage is a linkage in which a sequence is connected to a regulatory sequence (or sequences) in such a way as to place expression of the sequence under the influence or control of the regulatory sequence.
  • Two DNA sequences (such as a human secretory granule proteoglycan peptide core protein encoding sequence and a promoter region sequence linked to the 5' end of the encoding sequence) are said to be operably linked if induction of promoter function results in the transcription of the human secretory granule proteoglycan peptide core protein encoding sequence mRNA and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) in terfere with the ability of the expression regulatory sequences to direct the expression of the human secretory granule proteoglycan mRNA, antisense RNA, or protein, or (3) interfere with the ability of the human secretory granule proteoglycan template to be transcribed by the
  • regulatory regions needed for gene expression may vary between species or cell types, but shall in general include, as necessary, 5' non-transcribing and 5' non-translating (non-coding) sequences involved with initiation of transcription and translation respectively, such as the TATA box, capping sequence, CAAT sequence, and the like.
  • 5' non- transcribing control sequences will include a region which contains a promoter for transcriptional control of the operably linked gene.
  • transcriptional and translational regulatory signals can also be derived from the genomic sequences of viruses which infect eukaryotic cells, such as adenovirus, bovine papilloma virus, Simian virus, herpes virus, or the like. Preferably, these regulatory signals are associated with a particular gene which is capable of a high level of expression in the host cell.
  • control regions may or may not provide an initiator methionine (AUG) codon, depending on whether the cloned sequence contains such a methionine.
  • Such regions will, in general, include a promoter region sufficient to direct the initiation of RNA synthesis in the host cell. Promoters from heterologous mammalian genes which encode mRNA product capable of translation are preferred, and especially, strong promoters such as the promoter for actin, collagen, myosin, etc., can be employed provided they also function as promoters in the host cell.
  • Preferred eukaryotic promoters include the promoter of the mouse metallothionein I gene (Hamer, D., et al., J.
  • TK promoter of Herpes virus (McKnight, S., Cell 31:355-365 (1982)); the SV40 early promoter (Benoist, C, et al., Nature (London) 290:304-310 (1981)); in yeast, the yeast gal4 gene promoter (Johnston, S.A., et al., Proc. Natl. Acad. Sci. (USA) 79:6971-6975 (1982); Silver, P.A., et al., Proc. Natl. Acad. Sci. (USA) 81:5951-5955 (1984)) or a glycolytic gene promoter may be used.
  • codons results either in a formation of a fusion protein (if the AUG codon is in the same reading frame as human secretory granule proteoglycan encoding DNA sequence) or a frame-shift mutation (if the AUG codon is not in the same reading frame as the human secretory granule proteoglycan encoding sequence).
  • a fusion product of the human secretory granule proteoglycan peptide core protein may be constructed.
  • the sequence coding for human secretory granule proteoglycan peptide core protein may be linked to a signal sequence which will allow secretion of the protein from, or the compartmentalization of the protein in, a particular host.
  • signal sequences may be designed with or without specific protease sites such that the signal peptide sequence is amenable to subsequent removal.
  • the native signal sequence for this protein may be used.
  • Transcriptional initiation regulatory signals can be selected which allow for repression or activation, so that expression of the operably linked genes can be modulated.
  • regulatory signals which are temperature-sensitive so that by varying the temperature, expression can be repressed or initiated, or are subject to chemical regulation, e.g., metabolite.
  • constructs wherein both the human secretory granule proteoglycan peptide core protein mRNA and antisense RNA are provided in a transcribable forms but with different promoters or other transcriptional regulatory elements such that induction of human secretory granule proteoglycan peptide core protein mRNA expression is accompanied by repression of antisense RNA expression, and/or, repression of human secretory granule proteoglycan peptide core protein mRNA expression is accompanied by induction of antisense RNA expression.
  • Translational signals are not necessary when it is desired to express human secretory granule proteoglycan peptide core protein antisense RNA sequences.
  • the non-transcribed and/or non-translated regions 3' to the sequence coding for human secretory granule proteoglycan peptide core protein can be obtained by the above-described cloning methods.
  • the 3'-non-transcribed region may be retained for its transcriptional termination regulatory sequence elements; the 3-non-translated region may be retained for its translational termination regulatory sequence elements, or for those elements which direct polyadenylation in eukaryotic cells. Where the native expression control sequences signals do not function satisfactorily host cell, then sequences functional in the host cell may be substituted.
  • the vectors of the invention may further comprise other operably linked regulatory elements such as enhancer sequences, or DNA elements which confer tissue or cell -type specific expression on an operably linked gene.
  • the human secretory granule proteoglycan DNA encoding sequence and an operably linked promoter is introduced into a recipient eukaryotic cell as a non-replicating DNA (or RNA) molecule, which may either be a linear molecule or, more preferably, a closed covalent circular molecule which is incapable of autonomous replication, the expression of the human secretory granule proteoglycan protein may occur through the transient expression of the introduced sequence.
  • a non-replicating DNA (or RNA) molecule which may either be a linear molecule or, more preferably, a closed covalent circular molecule which is incapable of autonomous replication
  • genetically stable transformants may be constructed with vector systems, or transformation systems, whereby human secretory granule proteoglycan peptide core protein DNA is integrated into the host chromosome.
  • Such integration may occur de novo within the cell or , in a most preferred embodiment, be assisted by transformation with a vector which functionally inserts itself into the host chromosome, for example, with retroviral vectors, transposons or other DNA elements which promote integration of DNA sequences in chromosomes.
  • a vector is employed which is capable of integrating the desired gene sequences into a mammalian host cell chromosome.
  • Cells which have stably integrated the introduced DNA into their chromosomes are selected by also introducing one or more markers which allow for selection of host cells which contain the expression vector in the chromosome, for example the marker may provide biocide resistance, e.g., resistance to antibiotics, or heavy metals, such as copper, or the like.
  • the selectable marker gene can either be directly linked to the DNA gene sequences to be expressed, or introduced into the same cell by co-transfection.
  • the introduced sequence is incorporated into a plasmid or viral vector capable of autonomous replication in the recipient host.
  • a plasmid or viral vector capable of autonomous replication in the recipient host. Any of a wide variety of vectors may be employed for this purpose, as outlined below.
  • Factors of importance in selecting a particular plasmid or viral vector include: the ease with which recipient cells that contain the vector may be recognized and selected from those recipient cells which do not contain the vector; the number of copies of the vector which are desired in a particular host; and whether it is desirable to be able to "shuttle" the vector between host cells of different species.
  • Preferred eukaryotic plasmids include those derived from the bovine papilloma virus, vaccinia virus, SV40, and, in yeast, plasmids containing the 2-micron circle, etc., or their derivatives.
  • Such plasmids are well known in the art (Botstein, D., et al., Miami Wntr. Svmp. 19:265-274 (1982); Broach, J.R., In: The Molecular Biology of the Yeast Saccharomyces: Life Cycle and Inheritance. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, p.
  • mammalian expression vector systems which utilize the MSV-LTR promoter to drive expression of the cloned gene, and in which it is possible to cotrans- fect with a helper virus to amplify plasmid copy number, and, integrate the plasmid into the chromosomes of host cells have been described (Perkins, A.S. et al., Mol . Cell Biol. 3:1123 (1983); Clontech, Palo Alto, California).
  • the DNA construct(s) is introduced into an appropriate host cell by any of a variety of suitable means, including transfection. After the introduction of the vector, recipient cells are grown in a selective medium, which selects for the growth of vector-containing cells. Expression of the cloned gene sequence(s) results in the production of the human secretory granule proteoglycan peptide core protein, or in the production of a fragment of this protein. This expression can take place in a continuous manner in the transformed cells, or in a controlled manner, for example, expression which follows induction of differentiation of the transformed cells (for example, by administration of bromodeoxyuracil to neuroblastoma cells or the like). The expressed protein is isolated and purified in accordance with conventional conditions, such as extraction, precipitation, chromatography, affinity chromatography, electrophoresis, or the like.
  • the human secretory granule proteoglycan DNA encoding sequences will provide sequences which by definition, encode human secretory granule proteoglycan peptide core protein and which may then be used to obtain human secretory granule proteoglycan peptide core protein antisense RNA genetic sequences as the antisense RNA sequence will be that sequence found on the opposite strand of the strand transcribing the peptide core's mRNA.
  • the antisense DNA strand may also be operably linked to a promoter in an expression vector such that transformation with this vector results in a host capable of expression of a human secretory granule proteoglycan antisense RNA in the transformed cell.
  • Antisense RNA and its expression may be used to interact with an endogenous human secretory granule proteoglycan peptide core DNA or RNA in a manner which inhibits or represses transcription or translation of the secretory granule proteoglycan peptide core gene in a highly specific manner.
  • Use of antisense RNA probes to block gene expression is discussed in Lichtenstein, C., Nature 333:801-802 (1988).
  • An antibody is said to be “capable of binding” a molecule if it is capable of specifically reacting with the molecule to thereby bind the molecule to the antibody.
  • epitope is meant to refer to that portion of a hapten which can be recognized and bound by an antibody.
  • An antigen may have one, or more than one epitope.
  • An "antigen” is capable of inducing an animal to produce antibody capable of binding to an epitope of that antigen.
  • the specific reaction referred to above is meant to indicate that the antigen will react, in a highly selective manner, with its corresponding antibody and not with the multitude of other antibodies which may be evoked by other antigens.
  • antibody or “monoclonal antibody” (Mab) as used herein is meant to include intact molecules as well as fragments thereof (such as, for example, Fab and F(ab')2 fragments) which are capable of binding an antigen.
  • Fab and F(ab')2 fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding of an intact antibody (Wahl et al., J. Nucl. Med. 24:316-325 (1983)).
  • the antibodies of the present invention are prepared by any of a variety of methods.
  • cells expressing human secretory granule proteoglycan peptide core protein, or a fragment thereof can be administered to an animal in order to induce the production of sera containing polyclonal antibodies that are capable of binding human secretory granule proteoglycan.
  • a human secretory granule proteoglycan peptide core protein fragment is chemically synthesized and purified by HPLC to render it substantially free of contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of high specific activity.
  • Monoclonal antibodies can be prepared using hybridoma technology (Kohler et al., Nature 256:495 (1975); Kohler et al., Eur. J. Immunol. 6:511 (1976); Kohler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., In: Monoclonal Antibodies and T-Cell Hvbridomas. Elsevier, N.Y., pp. 563-681 (1981)).
  • such procedures involve immunizing an animal with human secretory granule proteoglycan antigen. The splenocytes of such animals are extracted and fused with a suitable myeloma cell line.
  • any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP 2 O), available from the American Type Culture Collection, Rockville, Maryland.
  • SP 2 O parent myeloma cell line
  • the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands, J.R., et al., Gastroenterology 80:225-232 (1981), which reference is herein incorporated by reference).
  • the hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the human secretory granule proteoglycan antigen.
  • Antibodies against both highly conserved and poorly conserved regions of the human proteoglycan peptide core are useful for studies on the control of biosynthesis and catabolism of human secretory granule proteoglycans in normal and pathologic conditions. Further, these antibodies can be used clinically to monitor the progress of disease states wherein the expression of human secretory granule proteoglycan peptide core protein is aberrant.
  • the promyelocytic leukemia cell line, HL-60 is a transformed human cell that synthesizes chondroitin sulfate proteoglycans and stores these proteoglycans in its secretory granules. Under certain in vitro conditions, this cell can be induced to differentiate into cells that resemble neutrophils, monocytes, macrophages, eosinophils, and basophils.
  • HL-60 cells line CCL 240; American Tissue Type Collection, Rockville, MD
  • BBL guanidine isothiocynate
  • total RNA was purified by the CsCl density-gradient centrifugation technique of Chirgwin et al., Biochemistry 18:5294 (1979).
  • cDNAs were blunt ended with T4 DNA polymerase (Biolabs, Beverly, MA), the internal EcoRI sites methylated, and the cDNAs ligated to EcoRI poly-linkers.
  • T4 DNA polymerase Biolabs, Beverly, MA
  • the cDNAs were ligated to dephosphorylated ⁇ gt10 DNA.
  • Escherichia coli strain C600 Hfl
  • the HL-60 cell -derived cDNA library was probed at 37oC with [ ⁇ - 32 P]dCTP (3000 Ci/mmol; New England Nuclear, Boston, MA) nick-translated pPG-1 in hybridization buffer (50% formamide, 5X SSC (0.15 M NaCl/15 mM sodium citrate), 2X Denhardt's buffer, 0.1% sodium dodecyl sulfate (SDS), 1 mM EDTA, 100 ⁇ g/ml salmon sperm DNA carrier, and 10 mM sodium phosphate).
  • the filters were washed at 37oC under conditions of low stringency of 1.0X SSC, 0.1% SDS, 1 mM EDTA, and 10 mM sodium phosphate, pH 7.0.
  • cDNA-H4 Approximately 500,000 recombinants in the library were plated to isolate the clone designated cDNA-H4 ( Figure 1).
  • the HL-60 cell-derived cDNA library (-500,000 recombinants) were rescreened using cDNA-H4 as the probe.
  • Thirty clones that hybridized under conditions of high stringency 55oC; 0.2X SSC, 1 mM EDTA, 0.1% SDS, and 10 mM sodium phosphate, pH 7.0
  • CDNA-H4 were isolated from the secondary screening of the library.
  • a 249 bp EcoRI-->EcoRI fragment has been isolated from a EcoRI digest of CDNA-H19.
  • the nucleotide sequence of this fragment (Table I) contains the sequence expected for a polyadenylation site (underlined) and the poly(A) + tail (underlined). This fragment hybridizes to a genomic fragment that encodes the gene for this proteoglycan peptide core, and thus probably represents the last 249 bp of the transcript.
  • Consensus nucleotide sequence of the 3' end of the cDNA that encodes the peptide core of the HL-60 secretory granule proteoglycan (Avraham, S. et al .. Proc. Natl . Acad. Sci . USA 86:3763-3767 (1989) ) .
  • the resulting fragments were resolved by agarose gel electrophoresis, and the DNA blots were analyzed under conditions of high stringency using cDNA-H4 as a probe.
  • the percent discordance of the cDNA-H4 probe to each human chromosome was determined as described in Table II; a discordant fraction of 0.00 indicates that, in HL-60 cells, the secretory granule proteoglycan peptide core gene is located on chromosome 10.
  • the DNA from different human/hamster and human/mouse somatic hybrid cell lines and the DNA from the controls were analyzed for their hybridization to CDNA-H4.
  • the column designations are: +/+, both hybridization to cDNA/cDNA-H4 and the specific human chromosome are present; -/-, hybridization to the cDNA-H4 and the chromosome are both absent; +/-, hybridization is present but the chromosome is absent; and -/+, hybridization is absent but the chromosome is present.
  • the sum of the +/- and -/+ columns are divided by the sum of the +/+, -/-, +/-, and -/- columns.
  • the 19q+ category represents the der 19 trans!ocation chromosomes for the hybrid clones derived from fusions with leukocytes from the two different X/19 translocation carriers.
  • the X and Xq- categories represent the intact X and the der X translocation chromosomes. Bruns et al., Biochem Genet. 17:1031- 1059 (1979).
  • Nitrocellulose filters (Millipore, Bedford, MA) were probed at 42oC in 50% formamide, 0.75 M NaCl , 75 mM sodium citrate, 5X Denhardt's buffer, 0.1% SDS, 1 mM EDTA, 100 ⁇ g/ml salmon sperm DNA carrier, and 10 mM sodium phosphate.
  • nitrocellulose filters were washed at 55oC with 30 mM NaCl, 3 mM sodium citrate, 0.1% SDS, 1 mM EDTA, and 10 mM sodium phosphate, pH 7.0.
  • Several independent clones were obtained using the entire 650 base pair (bp) HL-60 cell -derived cDNA, cDNA-H4.
  • the human genomic library was rescreened using the 136 bp 5'-->KpnI fragment of cDNA-H4 to isolate 2 additional clones.
  • the restriction maps of the clones were determined by incubating samples of their DNA separately with AceI. BamHI. EcoRI. Hindlll.
  • oligonucleotide Synthesizer Based on the nucleotide sequences of the sense strand and the antisense strand of the genomic fragment, two ol igonucleotide that were each 18 nucleotides in length were synthesized on an Applied Biosystems 380A Oligonucleotide Synthesizer at the Harvard Microchemi- stry Facility, Cambridge, MA. These oligonucleotides were then used as primers to determine the contiguous nucleotide sequence of the next 200-250 nucleotides in each direction of the double stranded DNA. Additional oligonucleotides complementary to different regions of the cDNA were used as primers to extend the sequence from the exons in both directions.
  • Nucleotide sequence data was entered and edited on an IBM-PC using the Clatech molecular biology software package. Data base searches and homology comparisons with the mouse secretory granule proteoglycan peptide core gene and other genes were performed using the computers at the Molecular Biology Computer Research Resource at Dana-Farber Cancer Institute, Boston, MA.
  • Exon 2 encodes a 49 amino acid portion of the peptide core (amino acid residues 28 to 76) which would be predicted to be the N-terminus of the molecule after the hydrophobic signal peptide is removed in the endoplasmic reticulum.
  • Exon 3 (634 bp) is the largest exon and encodes the remaining 82 amino acids of the translated molecule and the entire 3' untranslated region of the mRNA transcript.
  • These 82 amino acids encode a 17 amino acid sequence (residues 77 to 93) that immediately precedes the serine-glycine rich glycosaminoglycan attachment region, the 18 amino acid serine-glycine rich region (residues 94 to 111), the C-terminus of the translated molecule (residues 112 to 158).
  • a S1 nuclease mapping analysis was performed to identify the transcription- initiation site of the human gene that encodes the peptide core of secretory granule proteoglycans in HL-60 cells.
  • a 4 kb SaIl --> HindIII fragment of the genomic clone ⁇ HG-PG7 was subcloned into Bluescript (designated pB5SH3).
  • An oligonucleotide (5'-->ACTGCATTT GAGTAGCTT-->3') was synthesized that corresponded to the residues 39 to 59 of the antisense strand of cDNA-H4.
  • HL-60 cell-derived total RNA and poly(A) + RNA protected -82 nucleotides of the probe from degradation by S1 nuclease. Therefore, it was concluded that the putative transcription-initiation site in HL-60 cells for this gene resided 53 bp upstream of the translationinitiation site.
  • the 32 P-labeled 5' antisense 400 bp DNA fragment was not protected if it was incubated with tRNA or mouse mast cell RNA prior to exposure to SI nuclease.
  • This deduced transcription-initiation site in HL-60 cells corresponds to the deduced transcription- initiation site of the analogous gene that is expressed in BMMC-derived mast cells and rat basophilic leukemia cells (Bourdon, M.A. et al., Mol. Cell Biol. 7:33-40 (1987)), but not in rat L2 yolk sac tumor cells (Bourdon, M.A. et al., Mol. Cell Biol. 7:33-40 (1987)).
  • Figure 3 is a restriction map of the human gene.
  • Figure 4 is the nucleotide sequence of the gene that encodes the human secretory granule proteoglycan peptide core protein including flanking and intron sequences.
  • a 15 kb mouse genomic fragment containing the gene that encodes the mouse secretory granule proteoglycan peptide core protein was cloned by screening a mouse genomic library derived from a Sau3AI digest of BALB/c mouse liver DNA (Avraham, S., et al., Proc. Natl. Acad. Sci. USA 86:3763-3767 (1989)), using a [ ⁇ - 32 P]dCTP labeled 450 bp Accl—>3' gene-specific fragment of a BMMC cDNA (cDNA-M6) that encodes the peptide core of mouse secretory granule proteoglycan using methods as described above.
  • the nucleotide sequence and the deduced amino acid sequence of this gene is presented in Figure 5.
  • nucleotide sequences within these 5' flanking areas of the human and mouse secretory granule proteoglycan peptide core genes that are identical to several known cis acting regulatory elements for other genes.
  • 96% of the nucleotides that are present in a 119 bp nucleotide sequence just upstream of the transcription-initiation site of the human (residues -1 to -119) and mouse (residues -1 to -123) gene are identical. This degree of conservation greatly exceeds that obtained when any other 119 bp region within the exons of the gene in these two species is compared, and suggests that important cis acting regulatory elements are present in this conserved nucleotide sequence.
  • Rat-1 Fibroblasts with the Mouse Secretory Proteoglycan Peptide Core Gene.
  • Fisher rat-1 fibroblasts were grown in Dulbecco's modified essential medium (DMEM) supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml of penicillin, and 100 ⁇ g/ml of streptomycin, at 37oC in a humidified atmosphere of 5% CO 2 .
  • DNA cotransfections were performed essentially as described elsewhere (Southern, P.J. et al., J. Mol. APPI . Gen. 1:327-341 (1982)).
  • 3-4 x 10 5 rat-1 fibroblasts were placed into each 10-cm plastic culture dish containing DMEM for 12-24 h before cotransfection with the mouse genomic clone ⁇ MG-PGl and the selectable maker pSV2 neo.
  • a calcium phosphate/DNA precipitate was created by adding 0.5 ml of a 250-mM solution of calcium phosphate containing 5 ⁇ g of the ⁇ MG-PGl DNA and 0.5 ⁇ g of pSV2 neo drop-wise in the presence of bubbling air to 0.5 ml of 280 mM NaCl, 10 mM KCl, 12 mM dextrose, 1.5 mM sodium phosphate, and 50 mM HEPES (pH 7.1). The precipitate that formed after a 30 min incubation was added to a culture dish of fibroblasts, and 10 to 18 h later, the DNA precipitate was removed.
  • the trans- fected cells were washed twice with growth medium and then were allowed to recover for 24 h before being trypsinized and split at a ratio of 1:6.
  • the resulting fibroblasts were plated into new 10-cm plastic dishes and cultured for 2 to 3 wk in DMEM containing 500 ⁇ g/ml gentamicin (Gibco); the culture medium was changed every 3 days. At the end of this period, gentamicin-resistant colonies of transfected fibroblasts were individually picked with cloning cylinders and grown as cell lines in culture medium containing 100 ⁇ g/ml gentamicin.
  • RNA and DNA Blot Analysis of Rat-1 Fibroblasts Transfected with the Mouse Proteoglycan Gene were prepared from mouse BMMC, rat-1 fibroblasts, and transfected rat-1 fibroblasts by a guanidinium thiocyanate method (Chirgin, J.M. et al., Biochemistry 18:5294-5299 (1979); Glisin, V. et al., Biochemistry 13:2633-2637 (1974)).
  • RNA (5 ⁇ g/lane) was electrophoresed in 1% formaldehyde-agarose gels, and transferred to Zetabind (Thomas, P.S., Proc. Natl. Acad. Sci.
  • RNA blots were incubated at 42oC for 24 h in hybridization buffer containing a radiolabeled Accl -->3' fragment of CDNA-M6.
  • the blots were washed under conditions of high stringency, and autoradiography was performed.
  • the proteoglycan peptide core probe was removed from the blots by high temperature washing, and the blots were reprobed with an actin cDNA to quantitate the amount of mRNA that had been loaded in each lane.
  • DNA was isolated (Blin, N. et al., Nucleic Acids Res. 3:2303-2308 (1976)) from the mouse liver, rat liver, rat-1 fibroblasts, and transfected rat-1 fibroblasts, and samples were digested (10 ⁇ g/digest) separately with Xmnl. BamHI. BolII. Ssol. Sau3AI. Hindlll. or EcoRI for 4 h at 37oC. The fragments were resolved by agarose gel electrophoresis and were transferred to Zetabind. The resulting DNA blots were analyzed for hybridization under conditions of high stringency with the Accl-->3' fragment of the mouse CDNA-M6 as a probe.
  • rat-1 fibroblasts were cotransfected with ⁇ MG-PGl and the dominant neo-resistant selectable marker encoded by the plasmid pSV2 neo. Seventeen independent clones of neo-resistant transfected rat-1 fibroblasts were isolated and were expanded separately. Total RNA was isolated from BMMC, neo-transfected rat-1 fibroblasts, and the cotransfected rat-1 fibroblast cell lines.
  • the gene-specific secretory granule proteoglycan peptide core probe failed to hybridize to any transcript in RNA blots of non-transfected fibroblasts; however, it did hybridize to a 1.0-kb RNA transcript in mouse BMMC and in two of the cotransfected rat-1 fibroblast cell lines.
  • Primer extension analyses were performed using RNA from the transfected fibroblasts to determine the transcription- initiation site. When RNA from the transfected cells was used as an RNA template, -80 nucleotides were extended onto the oligonucleotide primer that corresponded to residues 78 to 98 of cDNA-M6, resulting in a DNA product of -100 nucleotides in length. A DNA product of ⁇ 60 nucleotides was obtain when the alternative primer that corresponded to residues 39 to 59 of CDNA-M6 was used in the assay.
  • Genomic DNA was prepared from the above two clones of transfected rat-1 fibroblasts, and was digested with Bglll, Xmnl, SalI, or BamHI. DNA blots of the digests were probed with the Accl -->3' gene-specific fragment of cDNA-M6 to demonstrate that these transfected rat-1 fibroblast cell lines contained in mouse proteoglycan genomic sequences.
  • the mouse proteoglycan probe hybridized to a 2.7-kb fragment present in the Bglll digest of mouse live DNA, and to a 7.5- kb fragment in the Bglll digests of both rat liver DNA and rat-1 fibroblast DNA.
  • the transfected fibroblasts differed from the non- transfected rat-1 fibroblasts in that they contained both the 2.7-kb and the 7.5-kb DNA fragments. Based on the relative intensity of hybridization of the gene-specific probe to the 2.7-kb fragment present in the BgIII digests of equal amounts of mouse liver DNA and fibroblast DNA, the fibroblast cell lines may have incorporated 10-20 and 2-3 copies, respectively, of the mouse secretory granule proteoglycan peptide core gene into their genome.
  • Transfections have been performed in Chinese hamster ovary cells with a cDNA that encodes the peptide core of the fibroblast-derived dermatan sulfate proteoglycan called decorin (Yamaguchi, Y. et al., Nature 336:244-246 (1988)) and in COS-7 cells with a cDNA that encodes the peptide core of the T-cell derived invariant chain proteoglycan that associates with la (Miller, J. et al., Proc. Natl. Acad. Sci. USA 85:1359-1363 (1988)), but no transfections have been reported using a genomic clone that contains an entire proteoglycan peptide core gene.
  • the induction of antibodies which specifically recognize the peptide core protein of human secretory granule proteoglycan was tested as follows.
  • the peptide (3 mg) was coupled with 5 mg of Keyhole Limpet hemocyanin (Sigma) in the presence of 0.25% glutar-aldehyde, and polyclonal antibodies were raised to the coupled peptide in New Zealand White rabbits using standard immunization methodologies.
  • Antibody titers in whole sera were measured using an enzyme linked immunosorbent assay (ELISA). Each microtiter well was incubated overnight at 4oC with 1 ⁇ g of synthetic peptide in phosphate buffered saline.
  • Peptide 01 (Ser-Val-Gln-Gly-Tyr-Pro-Thr-Gln-Arg-Ala-Arg-Tyr-Gln-Trp-Val-Arg) that corresponded to residues 24 to 39 of the deduced amino acid of cDNA-H4 was also synthesized and used in the ELISA to confirm the specificity of the rabbit antisera.
  • Anti-peptide IgG was partially purified by ammonium sulfate precipitation followed by ion exchange chromatography.
  • Anti-peptide IgG (-30 ⁇ g) was incubated with 100 ⁇ l of a 15% (w/v) suspension of the Protein A-Sepharose beads (Sigma) in RIPA buffer for 1 h at room temperature.
  • the resulting Protein A-Sepharose-IgG complex was added to 1 ml of RIPA cell lysates containing 5 ⁇ 10 6 cell equivalents of [ 35 S]methionine-labeled or [ 35 S]sulfate- labeled HL-60 cells that had been precleared by incubation for 24 h with Protein A-Sepharose alone and then for 24 h with Protein A- Sepharose/preimmune IgG.
  • the beads were washed 3 times by centrifugation with 0.1% bovine serum albumin, 0.5% Tween 20, and 10 mM phosphate buffered saline (pH 7.2) containing either 10 mM un- labeled methionine or unlabeled sodium sulfate.
  • the bound radio- labeled antigens were eluted by suspending the beads in 60 ⁇ l of Laemmli buffer and incubating for 5 min at 95oC.
  • the eluates were electrophoresed in 15% SDS-PAGE gels, stained with Coomassie Brilliant blue, dried, and autoradiographed using Kodak XAR-5 film.
  • the antiserum gave half-maximal binding at an approximate 500 fold dilution ( Figure 6).
  • the anti-peptide 02 serum failed to recognize peptide 01 which corresponded to deduced amino acid residues 24 to 39 of the same cDNA ( Figure 6).
  • the preimmune sera also failed to react with the coupled peptide 02. When 1 ⁇ l of the antisera was preincubated with 1 ⁇ g of peptide 02 for 60 minutes at 25oC, no immunoreactivity was detected in the ELISA.
  • the [ 35 S]methionine-labeled macromolecule corresponded in size exactly to the [ 35 S]sulfate-labeled proteoglycan that was precipitated after an overnight radiolabeling of the cells with [ 35 S]sulfate. Because precipitation was inhibitable by preincubation of the Protein A-Sepharose- immune IgG with 1 ⁇ g of the synthetic peptide 01, it was concluded that the rabbit anti-peptide 02 antibodies recognize the precursor and mature HL-60 cell proteoglycan peptide core.
  • the size of the immunoprecipitated peptide core protein was approximately 13,000 daltons, consistent with the size predicted by Stevens et al., J. Biol. Chem. 263:7287 (1988) for the peptide core which has lost its 27 amino acid signal peptide.
  • Human proteoglycan peptide core protein can be isolated using common protein isolation techniques known in the art such as column chromatography, gel electrophoresis, affinity chromatography, or immuno-extraction techniques using the antibody described above.
  • proteoglycans may be extracted by the following procedure (Stevens, R.L., et al., J. Biol. Chem. 260:14194-14200 (1985)).
  • BMMC pellets are lysed by resuspension for 30 s in 50 ⁇ l of 1% Zwittergent 3-12 containing protease inhibitors, followed by the addition of 2.35 ml of 4 M guanidine HCl (GnHCl) containing CsCl (density 1.4 g/ml). These detergent-GnHCl proteoglycan extracts are then pooled such that in a typical experiment 48 ml of extract is obtained from approximately 2 X 10 9 BMMC, of which 3 X 10 7 are radiolabeled.
  • GnHCl guanidine HCl
  • the pooled extracts are centrifuged at 17oC for 48 h at 95,000 X g, and the gradients are divided in most experiments into two equal fractions termed D 1 (bottom) and D 2 (top), respectively.
  • the distribution of chondroitin sulfate E proteoglycan in fractions from the CsCl gradient or from subsequent ion exchange or gel filtration chromatography is determined by suspending a sample of each fraction in 12.5 ml of Hydrofluor and quantitating 35 S or 3 H radioactivity in the radiolabeled proteoglycan on a Tracor Analytic Mark III liquid scintillation counter. Protein is detected by the method of Lowry et al.
  • each CsCl gradient is placed in dialysis tubing of 50,000 M r cut-off and dialyzed at 4oC against 1 M NaCl for 24 h and then for an additional 24 h against 1 M urea containing 0.05 M Tris-HCl, pH 7.3.
  • the dialysate is adjusted to 4 M in urea by the addition of solid urea and applied to a 0.8 X 29-cm column of DEAE-52 previously equilibrated in 4 M urea, 0.05 M Tris-HCl, pH 7.8.
  • the ion exchange column is washed with 35 ml of 4 M urea, 0.05 M Tris-HCl, pH 7.8, and the chondroitin sulfate E proteoglycan eluted with a 180-ml linear gradient of NaCl (0-1.0 M) in the urea buffer at a flow rate of 4 ml/h.
  • Two-ml fractions are collected, and the proteoglycan-enriched fractions, detected by monitoring a portion of the fraction for either 35 S or 3 H radioactivity if the cells have been prelabelled, are pooled, dialyzed 48 h at 4oC against 0.1 M NH 4 HCO 3 , and lyophilized.
  • This material is redissolved in 100 ⁇ l of 4 M GnHCl/0.1 M sodium sulfate/0.1 M Tris-HCl, pH 7.0, applied to a 0.6 X 100-cm column of Sepharose CL-4B in this same buffer, and eluted from the column at a flow rate of 1.5 ml/h.
  • One-half ml fractions are collected and analyzed for radioactivity and absorbance at 280 nm.
  • the proteo-glycan-containing fractions are pooled, dialyzed against 0.1 M NH 4 HCO 3 and lyophilized.
  • Radiolabeling of HL-60 Cells--HL-60 cells were cultured in enriched medium [RPMI-1640 medium supplemented with 10% (v/v) fetal calf serum, 2 mM L-glutamine, 0.1 mM nonessential amino acids, 100 U/ml of penicillin, and 100 ⁇ g/ml of streptomycin (Gibco, Grand Island, NY)] at 37oC in a humidified atmosphere of 5% CO 2 .
  • HL-60 cells were preincubated at a concentration of 10 7 cells/ml for 10 min in methionine-free, enriched medium containing dialyzed fetal calf serum. Approximately 500 ⁇ Ci/ml of [ 35 S]methionine (129 Ci/mmol; Amersham, Arlington Heights, IL) was then added. The HL-60 cells were incubated for an additional 2 to 10 min at 37oC, centrifuged in the cold at 120 x g, and washed at 4oC in enriched medium.
  • HL-60 cells were [ 35 S]methionine-1abeled for 10 min, were washed as above, and were resuspended in normal enriched medium at 37oC for an additional 5 min. Aliquots of 5 x 10 6 [ 35 S]methionine-labeled HL-60 cells were lysed in 1 ml of RIPA buffer [0.15 M NaCl, 1% deoxycholate, 1% Nonident P-40, 0.1% SDS, 10 mM N-ethylmaleimide, 2 mM phenylmethylsulfonyl fluoride, 10 mM NaF, and 0.1 M Tris-HCl, pH 7.2], and immunoprecipitates of the lysates were analyzed by SDS-polyacryl amide gel electrophoresis (SDS-PAGE) as described below.
  • SDS-PAGE SDS-polyacryl amide gel electrophoresis
  • HL-60 cells were incubated in enriched medium containing 50 ⁇ Ci/ml of [ 35 S]sulfate (-4000 Ci/mmol; DuPont-New England Nuclear, Boston, MA) for 1 h at a density of 1 x 10 7 cells/ml or for 18 h at a density of 2 x 10 6 cells/ml.
  • the radiolabeled cells were centrifuged at 4oC for 10 min at 120 x g, and 150 ⁇ l of 1% (w/v) zwittergent 3-12 (Calbiochem, San Diego, CA) containing 100 ⁇ g of chondroitin sulfate A (Miles Scientific, Naperville, IL) and 100 ⁇ g of heparin (Sigma, St. Louis, MO) glycosaminoglycan carriers were added to each cell pellet followed by 1.35 ml of 4 M GnHCl, 0.1 M sodium sulfate, and 0.1 M Tris-HCl. A sample of each lysate and supernatant was chromatographed on Sephadex G-25/PD-10 columns (Pharmacia, Piscataway, NJ) to quantitate the incorporation of [35 S]sulfate into macromolecules.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne l'identification, la caractérisation et le classement de séquences génétiques de la protéine du noyau peptidique des protéoglycanes humains de la granule sécrétoire, des clones D'ADN recombinant dirigés contre cette séquence et contre la séquence de l'ARN antisensoriel, et des anticorps reconnaissant les protéoglycanes humains natifs de la granule secrétoire.
PCT/US1989/003051 1988-07-13 1989-07-13 Polynucleotides codant le noyau peptidique de proteoglycanes humains des cellules effectrices de la reponse immunitaire WO1990000606A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22403588A 1988-07-13 1988-07-13
US224,035 1988-07-13

Publications (1)

Publication Number Publication Date
WO1990000606A1 true WO1990000606A1 (fr) 1990-01-25

Family

ID=22839033

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/003051 WO1990000606A1 (fr) 1988-07-13 1989-07-13 Polynucleotides codant le noyau peptidique de proteoglycanes humains des cellules effectrices de la reponse immunitaire

Country Status (4)

Country Link
EP (1) EP0435877A4 (fr)
JP (1) JPH04500904A (fr)
AU (1) AU4044289A (fr)
WO (1) WO1990000606A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0505552A1 (fr) * 1990-10-12 1992-09-30 Amgen Inc. Facteurs de maturation de megacaryocytes
WO1993013119A1 (fr) * 1992-01-03 1993-07-08 Brigham And Women's Hospital Elements regulateurs de transcription provenant de la serglycine et specifiques des cellules hematopoietiques, et utilisations de ces elements
WO1994003601A2 (fr) * 1992-08-03 1994-02-17 New York University Clonage, expression et utilisation de neurocan en tant que proteoglycane de sulfate de chondroitine
US5317085A (en) * 1988-07-13 1994-05-31 Brigham And Women's Hospital Polynucleotides that encode the human proteoglycan peptide core of the effector cells of the immune response

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS Volume 103 (25) issued 23 December 1985 LUIKART "Altered Glycosaminoglycan Production by HL-60 Cells Treated with 4-Methylumbelliferyl -B-D-Xyloside". see page 647. *
Febs Letters Volume 236 issued August 1988 ALLIEL "Complete Amino Acid Sequence of Human Platelet Proteoglycan" see pages 123-126, particularly figure 2. *
Federal Proceedings Volume 45(3) issued 1986 TANTRAVATTI "Molecular Analysis of the Gene Encoding the Proteoglycans Expressed in Rat and Murine Mast Cells" see page 626. *
Journal of Biological Chemistry Volume 260(26) issued 15 November 1985 STEVENS "Purification and Analysis of the Core Protein of the Protease-Resistant Intracellular Chondroitin Sulfate E Proteoglycan from the Interleukin 3-Dependent Mouse Mast Cell" see pages 14190-14200. *
Journal of Biological Chemistry Volume 261(27) issued 25 September 1986 BOURDON "Identification from cDNA of the Precursor form of a Chaondroitin Sulfate Proteoglycan Core Protein" see pages 12534-12537, particularly figures 1-2. *
Journal of Biological Chemistry Volume 263(15) issued 25 May 1988 STEVENS "Isolation and Characterization of a cDNA that Encodes the Peptide Core of the Secretary Granule Proteoglycan of Human Promyelocytic Leukemia HL-60 Cells" see pages 7287-7291 particularly figure 2 and table 1. *
Journal of Experimental Medicine Volume 163 issued November 1986 GIACOLETTO "The Human Inuariant Chain is the Core Protein of the Human Class II-Associated Proteoglycan". see pages 1422-1439 particularly figures 1 and 2. *
Molecular and Cellular Biology Volume 7 (1) issued January 1987 BOURDON "Gene Expression of the Chondroitin Sulfate Proteoglycan Core Protein PG 19" see pages 33-40. *
Proceedings of The National Academy of Sciences Volume 82 issued March 1985 BOURDON "Molecular Cloning and Sequence Analysis of a Chondroitin Sulfate Proteoglycan" see pages 1321-1325. *
Proceedings of The National Academy of Sciences Volume 83 issued December 1986 TANTRAVAHI "A Singel Gene in Mast Cells Encodes the Core Peptides of Heparin and Chondroitin Sulfate Proteoglycans" see pages 9207-9210. *
See also references of EP0435877A4 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5317085A (en) * 1988-07-13 1994-05-31 Brigham And Women's Hospital Polynucleotides that encode the human proteoglycan peptide core of the effector cells of the immune response
US5340739A (en) * 1988-07-13 1994-08-23 Brigham & Women's Hospital Hematopoietic cell specific transcriptional regulatory elements of serglycin and uses thereof
EP0505552A1 (fr) * 1990-10-12 1992-09-30 Amgen Inc. Facteurs de maturation de megacaryocytes
EP0505552A4 (en) * 1990-10-12 1994-06-08 Amgen Inc Megakaryocyte maturation factors
WO1993013119A1 (fr) * 1992-01-03 1993-07-08 Brigham And Women's Hospital Elements regulateurs de transcription provenant de la serglycine et specifiques des cellules hematopoietiques, et utilisations de ces elements
WO1994003601A2 (fr) * 1992-08-03 1994-02-17 New York University Clonage, expression et utilisation de neurocan en tant que proteoglycane de sulfate de chondroitine
US5648465A (en) * 1992-08-03 1997-07-15 New York University Cloning and expression of neurocan, a chondroitin sulfate proteoglycan
WO1994003601A3 (fr) * 1992-08-03 2001-05-17 Univ New York Clonage, expression et utilisation de neurocan en tant que proteoglycane de sulfate de chondroitine

Also Published As

Publication number Publication date
EP0435877A1 (fr) 1991-07-10
EP0435877A4 (en) 1992-03-11
AU4044289A (en) 1990-02-05
JPH04500904A (ja) 1992-02-20

Similar Documents

Publication Publication Date Title
Ghebrehiwet et al. Isolation, cDNA cloning, and overexpression of a 33-kD cell surface glycoprotein that binds to the globular" heads" of C1q.
US5340739A (en) Hematopoietic cell specific transcriptional regulatory elements of serglycin and uses thereof
JP3534406B2 (ja) 免疫グロブリンＥの高アフィニティレセプタのヒトβサブユニットの分離，特性化および用法
Devlin et al. Secretion of a soluble class I molecule encoded by the Q10 gene of the C57BL/10 mouse.
CA1341095C (fr) Adnc codant pour le facteur von willebrand humain, plasmides ou phages contenant respectivement cet adnc ou des fragments de ce dernier, microorganismes ou cellules animales ou humaines contenant les dits plasmides ou phages, preparation de proteines den cultivant les dits microorganismes ou cellules, les proteines obtenues et des compositions pharmaceutique
WO1992012175A1 (fr) Poteine induite par la cytokine, adn tsg-6 codant pour cette proteine et ses utilisations
US5171674A (en) Polynucleotides that encode the human proteoglycan peptide core of the effector cells of the immune response
Estaller et al. Cloning of the 1.4-kb mRNA species of human complement factor H reveals a novel member of the short consensus repeat family related to the carboxy terminal of the classical 150-kDa molecule.
EP0477739A2 (fr) Phospholipase D spécifique pour la glycosyl-phosphatidylinositol
EP0527813B1 (fr) CLONES D cDNA DE LYMPHOCYTES T DE LYMPHOME
Prabhakara Reddi et al. Complementary deoxyribonucleic acid cloning and characterization of mSP-10: the mouse homologue of human acrosomal protein SP-10
US6884872B1 (en) Methods and compositions relating to CD39-like polypeptides and nucleic acids
CA2086091A1 (fr) Proteine 2.beta. de macrophage humain
US6861254B1 (en) Heparan sulfate D-glucosaminyl 3-O-sulfotransferases, and uses therefor
JPH06501244A (ja) ヒトマクロファージ炎症性タンパク質２β
WO1990000606A1 (fr) Polynucleotides codant le noyau peptidique de proteoglycanes humains des cellules effectrices de la reponse immunitaire
WO1990002207A1 (fr) Antigene clone de la nephrite
WO1990007937A1 (fr) Applications de proteines specifiques a la grossesse
US20020146772A1 (en) Methods and materials relating to novel CD39-like polypeptides
US5317085A (en) Polynucleotides that encode the human proteoglycan peptide core of the effector cells of the immune response
WO1998033819A1 (fr) Recepteurs cellulaires des adenovirus du sous-groupe c et des virus coxsackie du groupe b
US6627735B2 (en) Islet cell antigen 1851
WO1999003883A1 (fr) Compositions et procedes faisant appel au gene de la sclerose tubereuse de bourneville-1 (tsc1) et produit genique
JP2552942B2 (ja) ヒトｂーＦＧＦ受容体遺伝子
US6184031B1 (en) DNA sequences that encode a natural resistance to infection with intracellular parasites

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1989909093

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989909093

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1989909093

Country of ref document: EP